{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:17:55Z","timestamp":1791299875925,"version":"4.1.0"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"DOI":"10.13039\/100011731","name":"Action for A-T","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011634","name":"Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Somatic variants in DNA damage response genes such as ATM are widespread in hematologic malignancies. ATM protein is essential for double-strand DNA break repair. Germline ATM deficiencies underlie ataxia\u2013telangiectasia (A\u2013T), a disease manifested by radiosensitivity, immunodeficiency, and predisposition to lymphoid malignancies. Patients with A\u2013T diagnosed with malignancies have poor tolerance to chemotherapy or radiation. In this study, we investigated chimeric antigen receptor (CAR) T cells using primary T cells from patients with A\u2013T (ATM\u2212\/\u2212), heterozygote donors (ATM+\/\u2212), and healthy donors. ATM\u2212\/\u2212 T cells proliferate and can be successfully transduced with CARs, though functional impairment of ATM\u2212\/\u2212 CAR T-cells was observed. Retroviral transduction of the CAR in ATM\u2212\/\u2212 T cells resulted in high rates of chromosomal lesions at CAR insertion sites, as confirmed by next-generation long-read sequencing. This work suggests that ATM is essential to preserve genome integrity of CAR T-cells during retroviral manufacturing, and its lack poses a risk of chromosomal translocations and potential leukemogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>CAR T-cells are clinically approved genetically modified cells, but the control of genome integrity remains largely uncharacterized. This study demonstrates that ATM deficiency marginally impairs CAR T-cell function and results in high rates of chromosomal aberrations after retroviral transduction, which may be of concern in patients with DNA repair deficiencies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0268","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:03:53Z","timestamp":1715760233000},"page":"267-275","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genotoxicity Associated with Retroviral CAR Transduction of\n                    <i>ATM<\/i>\n                    -Deficient T Cells"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3375-9393","authenticated-orcid":false,"given":"Meir","family":"Rozenbaum","sequence":"first","affiliation":[{"name":"Cell Therapy Lab, Sheba Medical Center, Tel Hashomer, Israel. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5566-5638","authenticated-orcid":false,"given":"Reut","family":"Fluss","sequence":"additional","affiliation":[{"name":"Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel. 2"},{"name":"Wohl Centre for Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-2492","authenticated-orcid":false,"given":"Victoria","family":"Marcu-Malina","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, Sheba Medical Center, Tel Hashomer, Israel. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0187-807X","authenticated-orcid":false,"given":"Ifat","family":"Sarouk","sequence":"additional","affiliation":[{"name":"National A-T Center, Pediatric Pulmonology Unit, The Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center, Tel Hashomer, Israel. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1225-965X","authenticated-orcid":false,"given":"Amilia","family":"Meir","sequence":"additional","affiliation":[{"name":"Cell Therapy Lab, Sheba Medical Center, Tel Hashomer, Israel. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-7578","authenticated-orcid":false,"given":"Sarah","family":"Elitzur","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, Schneider Children\u2019s Medical Center, Petah Tikva, Israel. 6"},{"name":"Faculty of Medicinal & Health Sciences, Tel Aviv University, Tel Aviv, Israel. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5580-5282","authenticated-orcid":false,"given":"Tal","family":"Zinger","sequence":"additional","affiliation":[{"name":"Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-7404","authenticated-orcid":false,"given":"Jasmine","family":"Jacob-Hirsch","sequence":"additional","affiliation":[{"name":"Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel. 2"},{"name":"Wohl Centre for Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-6106","authenticated-orcid":false,"given":"Efrat G.","family":"Saar","sequence":"additional","affiliation":[{"name":"Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel. 2"},{"name":"Wohl Centre for Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4594-1811","authenticated-orcid":false,"given":"Gideon","family":"Rechavi","sequence":"additional","affiliation":[{"name":"Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel. 2"},{"name":"Wohl Centre for Translational Medicine, Sheba Medical Center, Tel Hashomer, Israel. 3"},{"name":"Faculty of Medicinal & Health Sciences, Tel Aviv University, Tel Aviv, Israel. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-8942","authenticated-orcid":false,"given":"Elad","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Cell Therapy Lab, Sheba Medical Center, Tel Hashomer, Israel. 1"},{"name":"Faculty of Medicinal & Health Sciences, Tel Aviv University, Tel Aviv, Israel. 7"},{"name":"Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center, Tel Hashomer, Israel. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"2026041310141173400_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood.V87.2.423.bloodjournal872423","article-title":"Leukemia and lymphoma in ataxia telangiectasia","volume":"87","author":"Taylor","year":"1996","journal-title":"Blood"},{"key":"2026041310141173400_bib2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3109\/08880018.2013.777949","article-title":"Acute lymphoblastic leukemia in early childhood as the presenting sign of ataxia-telangiectasia variant","volume":"30","author":"Bielorai","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"2026041310141173400_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clim.2017.01.009","article-title":"Ataxia-telangiectasia: immunodeficiency and survival","volume":"178","author":"van Os","year":"2017","journal-title":"Clin Immunol"},{"issue":"Suppl 1","key":"2026041310141173400_bib4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1182\/blood-2023-179333","article-title":"ATM germline pathogenic variants affect treatment outcomes in children with acute lymphoblastic leukemia\/lymphoma and ataxia telangiectasia","volume":"142","author":"Elitzur","year":"2023","journal-title":"Blood"},{"key":"2026041310141173400_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041310141173400_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026041310141173400_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2026041310141173400_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026041310141173400_bib9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"key":"2026041310141173400_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature04866","article-title":"ATM stabilizes DNA double-strand-break complexes during V(D)J recombination","volume":"442","author":"Bredemeyer","year":"2006","journal-title":"Nature"},{"key":"2026041310141173400_bib11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaci.2013.01.053","article-title":"Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity","volume":"131","author":"Driessen","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2026041310141173400_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1742-4690-6-114","article-title":"DNA double strand break repair enzymes function at multiple steps in retroviral infection","volume":"6","author":"Sakurai","year":"2009","journal-title":"Retrovirology"},{"key":"2026041310141173400_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"2026041310141173400_bib14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"2026041310141173400_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"key":"2026041310141173400_bib16","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott\u2013Aldrich syndrome-long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026041310141173400_bib17","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"2026041310141173400_bib18","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1182\/bloodadvances.2022008093","article-title":"Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy","volume":"6","author":"Hsieh","year":"2022","journal-title":"Blood Adv"},{"key":"2026041310141173400_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"2026041310141173400_bib20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"key":"2026041310141173400_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/ncb1250","article-title":"Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase","volume":"7","author":"Lau","year":"2005","journal-title":"Nat Cell Biol"},{"key":"2026041310141173400_bib22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.22.00269","article-title":"Rare germline ATM variants influence the development of chronic lymphocytic leukemia","volume":"41","author":"Lampson","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041310141173400_bib23","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"2026041310141173400_bib24","doi-asserted-by":"crossref","first-page":"e000148","DOI":"10.1136\/jitc-2019-000148","article-title":"Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients","volume":"8","author":"Itzhaki","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026041310141173400_bib25","doi-asserted-by":"crossref","DOI":"10.1159\/isbn.978-3-318-05979-3","volume-title":"ISCN 2016: An international system for human cytogenomic nomenclature","author":"McGowan-Jordan","year":"2016"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0268\/3453464\/bcd-23-0268.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0268\/3462015\/bcd-23-0268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/4\/267\/3470416\/bcd-23-0268.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/4\/267\/3470416\/bcd-23-0268.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:14:19Z","timestamp":1776089659000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/4\/267\/746108\/Genotoxicity-Associated-with-Retroviral-CAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,9]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0268","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.26134501","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134492.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134489","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134510.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134513","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134504.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134504","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134489.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134507","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134507.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134495.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134498.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134501.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134492","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134513.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134495","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134498","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134510","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7309465.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.7309465","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}